Copertina

Approaches to repurposing reverse transcriptase antivirals in cancer

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Richard Head, Saiful Islam, Jennifer H. Martin
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	British Journal of Clinical Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Pharmacokinetic modelling to enable early attrition of repurposed antiviral drug combination candidates with a high likelihood of failure in COVID‐19
Pubblicazione: (2024)

Single‐ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non‐nucleoside reverse transcriptase inhibitor, for treatment of HIV‐1 infection
Pubblicazione: (2024)

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy
di: Ciara B. Blum, et al.
Pubblicazione: (2026)

Integrating generative AI and genetic causal inference identifies metformin as a repurposing candidate for normal tension glaucoma
di: Junhong Jiang, et al.
Pubblicazione: (2026)

The impact of pretreatment drug resistance on ainuovirine‐based antiviral therapy in HIV‐infected patients: A subgroup analysis from the RACER study
di: Q. Li, et al.
Pubblicazione: (2025)

Safety, pharmacokinetics and antiviral activity of ainuovirine as 10‐day monotherapy in treatment‐naïve adults with HIV‐1
Pubblicazione: (2024)

Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome
di: Maren Hermanns‐Clausen, et al.
Pubblicazione: (2026)

Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet‐α, protamine)
di: Elias Bekka, et al.
Pubblicazione: (2024)

Association between reversal agents (sugammadex vs. neostigmine) for neuromuscular block and postoperative pulmonary complications: A retrospective analysis
di: Aolin Ren, et al.
Pubblicazione: (2024)

Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model
di: Sara Merdita, et al.
Pubblicazione: (2024)

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales
di: Catrin O. Plumpton, et al.
Pubblicazione: (2026)

Sodium‐glucose cotransporter‐2 inhibitors and the risk of lung cancer among patients with type 2 diabetes
di: Samantha B. Shapiro, et al.
Pubblicazione: (2024)

Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen
di: Ya‐Ping Tu, et al.
Pubblicazione: (2024)

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer
di: Catharina J. P. Op 't Hoog, et al.
Pubblicazione: (2025)

Safe and supportive prescribing in transgender and non‐binary patients with cancer
di: Mariachiara D'Elia, et al.
Pubblicazione: (2024)

The association of pain impact and sleep disruption with opioid withdrawal during opioid‐use disorder treatment
di: Jennifer D. Ellis, et al.
Pubblicazione: (2024)

Comment on ‘Spotlight commentary: Addressing the persistent problem of benzodiazepine overuse, time for clinical, educational and AI‐driven reform’
di: Jennifer Koenig, et al.
Pubblicazione: (2026)

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients
di: Yong Jin Lim, et al.
Pubblicazione: (2026)

Reconsidering the microbial origins of primary sclerosing cholangitis and related autoimmune disorders: A case for the antro‐duodenal microbiome
di: Richard Kellermayer, et al.
Pubblicazione: (2025)

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study
di: Takashi Yokokawa, et al.
Pubblicazione: (2026)

Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide
di: Takehiro Miyagi, et al.
Pubblicazione: (2025)

A randomized controlled study of neoadjuvant metformin with chemotherapy in nondiabetic breast cancer women: The METNEO study
di: Manar A. Serageldin, et al.
Pubblicazione: (2024)

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials
di: Anna Margarete Maria Thurner, et al.
Pubblicazione: (2025)

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records
di: Alessandro De Carlo, et al.
Pubblicazione: (2025)

Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells
di: Marco Hoffmann, et al.
Pubblicazione: (2026)

Population pharmacokinetics and exposure–response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY
di: Mita Kuchimanchi, et al.
Pubblicazione: (2024)

Efficacy and safety of androgen receptor inhibitors for treatment of advanced prostate cancer: A systematic review and network meta‐analysis
di: Shichao Xiao, et al.
Pubblicazione: (2024)

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society
di: Dagan O. Lonsdale, et al.
Pubblicazione: (2026)

Comprehensive analysis of adverse event profile changes with pertuzumab addition to trastuzumab‐based breast cancer therapy: Disproportionality analysis using VigiBase
di: Tatsuaki Takeda, et al.
Pubblicazione: (2025)

Preliminary efficacy and safety profile of dual histamine blockade on preventing filgrastim‐associated bone pain in breast cancer patients: Randomized controlled trial
di: Mona M. Eltamalawy, et al.
Pubblicazione: (2025)

Longitudinal non‐cancer pain management patterns and risk of adverse outcomes in older adults: Insights from group‐based multi‐trajectory modelling
di: I‐Tzu Chen, et al.
Pubblicazione: (2025)

Model‐based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer
di: Yue Zhao, et al.
Pubblicazione: (2024)

Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus
di: Junyi Wu, et al.
Pubblicazione: (2024)

Frailty in clinical drug trials: Frailty assessments, subgroup analyses and outcomes
di: Tu N. Nguyen, et al.
Pubblicazione: (2024)

Pharmacokinetics of subcutaneous and intravenous bolus doses of morphine in palliative care cancer patients receiving infusion of morphine: A pharmacokinetic substudy of a randomized controlled trial
di: Eva Gravdahl, et al.
Pubblicazione: (2025)

Developing an international concept‐based curriculum for pharmacology education: The promise of core concepts and concept inventories
di: Clare Guilding, et al.
Pubblicazione: (2024)

Comment on: ‘alpha‐lipoic acid as a preventive measure in radiation‐induced oral mucositis in head and neck cancer pAtients: a randomized controlled study’—methodological considerations
di: Erkan Topkan, et al.
Pubblicazione: (2026)

Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiency
di: Annie Siyu Wu, et al.
Pubblicazione: (2025)

SLCO1B1 variants in a patient of African ancestry presenting with rosuvastatin‐induced rhabdomyolysis: A case report
di: Samantha Medwid, et al.
Pubblicazione: (2024)

Incorporating transgender and nonbinary participants in phase 1 clinical drug trials: Current knowledge gaps and considerations
di: Lauren E. Walker, et al.
Pubblicazione: (2024)